Pilot clinical study of the effects of ginger root extract on eicosanoids in colonic mucosa of subjects at increased risk for colorectal cancer

Molecular Carcinogenesis

Volumn 54, Issue 9, 2015, Pages 908-915

  Zick, Suzanna M ^a,b   Turgeon, D Kim ^a   Ren, Jianwei ^a   Ruffin, Mack T ^a   Wright, Benjamin D ^a   Sen, Ananda ^a   Djuric, Zora ^a,b   Brenner, Dean E ^a,c  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

And zingiber; Cancer risk reductive; Inflammation; Lipoxygenase; Prostaglandins

Indexed keywords

12 HYDROXYICOSATETRAENOIC ACID; 13 HYDROXYOCTADECADIENOIC ACID; 15 HYDROXYICOSATETRAENOIC ACID; 5 HYDROXYICOSATETRAENOIC ACID; ARACHIDONIC ACID; GINGER EXTRACT; GINGER ROOT EXTRACT; ICOSANOID; LEUKOTRIENE B4; PLACEBO; PROSTAGLANDIN E2; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; PLANT EXTRACT;

ADULT; AGED; ARTICLE; CANCER RISK; CHEMOPROPHYLAXIS; CLINICAL ARTICLE; CLINICAL STUDY; COLON ADENOMA; COLON BIOPSY; COLON MUCOSA; COLORECTAL CANCER; DRUG SAFETY; DRUG TOLERABILITY; ELECTROSPRAY MASS SPECTROMETRY; FEMALE; FIRST DEGREE RELATIVE; HUMAN; LIQUID CHROMATOGRAPHY; MALE; PILOT STUDY; PRIORITY JOURNAL; SIGMOIDOSCOPY; TREATMENT DURATION; CHEMISTRY; COLON; COLORECTAL NEOPLASMS; CONTROLLED STUDY; DRUG EFFECTS; GINGER; IMMUNOLOGY; INTESTINE MUCOSA; MIDDLE AGED; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; RECTUM;

ZINGIBER; ZINGIBER OFFICINALE;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTICARCINOGENIC AGENTS; COLON; COLORECTAL NEOPLASMS; EICOSANOIDS; FEMALE; GINGER; HUMANS; INTESTINAL MUCOSA; MALE; MIDDLE AGED; PILOT PROJECTS; PLANT EXTRACTS; RECTUM;

EID: 84938961535     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.22163     Document Type: Article

References (53)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11-30.
2. Elwood PC, Gallagher AM, Duthie GG, Mur LA, Morgan G. Aspirin, salicylates, and cancer. Lancet 2009; 373:1301-1309.
3. Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352:1071-1080.
4. James MW, Hawkey CJ. Assessment of non-steroidal anti-inflammatory drug (NSAID) damage in the human gastrointestinal tract. Br J Clin Pharmacol 2003; 56:146-155.
5. Cianchi F, Cortesini C, Fantappie O, et al. Cyclooxygenase-2 activation mediates the proangiogenic effect of nitric oxide in colorectal cancer. Clin Cancer Res 2004; 10:2694-2704.
6. Bortuzzo C, Hanif R, Kashfi K, Staiano-Coico L, Shiff SJ, Rigas B. The effect of leukotrienes B and selected HETEs on the proliferation of colon cancer cells. Biochim Biophys Acta 1996; 1300:240-246.
7. Nielsen CK, Campbell JI, Ohd JF, et al. A novel localization of the G-protein-coupled CysLT1 receptor in the nucleus of colorectal adenocarcinoma cells. Cancer Res 2005; 65:732-742.
8. Tong WG, Ding XZ, Talamonti MS, Bell RH, Adrian TE. LTB4 stimulates growth of human pancreatic cancer cells via MAPK and PI-3 kinase pathways. Biochem Biophys Res Commun 2005; 335:949-956.
9. Soumaoro LT, Iida S, Uetake H, et al. Expression of 5-lipoxygenase in human colorectal cancer. World J Gastroenterol 2006; 12:6355-6360.
10. Melstrom LG, Bentrem DJ, Salabat MR, et al. Overexpression of 5-lipoxygenase in colon polyps and cancer and the effect of 5-LOX inhibitors in vitro and in a murine model. Clin Cancer Res 2008; 14:6525-6530.
11. Ihara A, Wada K, Yoneda M, Fujisawa N, Takahashi H, Nakajima A. Blockade of leukotriene B4 signaling pathway induces apoptosis and suppresses cell proliferation in colon cancer. J Pharmacol Sci 2007; 103:24-32.
12. Gao P, Guan L, Zheng J. Role of leukotriene B4 in celecoxib-mediated anticancer effect. Biochem Biophys Res Commun 2010; 402:308-311.
13. Bhattacharya S, Mathew G, Jayne D, Pelengaris S, Khan M. 15-Lipoxygenase-1 in colorectal cancer: A review. Tumor Biol 2009; 30:185-199.
14. Il Lee S, Zuo X, Shureiqi I. 15-Lipoxygenase-1 as a tumor suppressor gene in colon cancer: Is the verdict in? Cancer Metastasis Rev 2011; 30:481-491.
15. Shureiqi I, Chen D, Day RS, et al. Profiling lipoxygenase metabolism in specific steps of colorectal tumorigenesis. Cancer Prev Res (Phila) 2010; 3:829-838.
16. Mascolo N, Jain R, Jain SC, Capasso F. Ethnopharmacologic investigation of ginger (Zingiber officinale). J Ethnopharmacol 1989; 27:129-140.
17. Kiuchi F, Shibuya M, Sankawa U. Inhibitors of prostaglandin biosynthesis from ginger. Chem Pharm Bull (Tokyo) 1982; 30:754-757.
18. Koo KL, Ammit AJ, Tran VH, Duke CC, Roufogalis BD. Gingerols and related analogues inhibit arachidonic acid-induced human platelet serotonin release and aggregation. Thromb Res 2001; 103:387-397.
19. Sharma JN, Srivastava KC, Gan EK. Suppressive effects of eugenol and ginger oil on arthritic rats. Pharmacology 1994; 49:314-318.
20. Nurtjahja-Tjendraputra E, Ammit AJ, Roufogalis BD, Tran VH, Duke CC. Effective anti-platelet and COX-1 enzyme inhibitors from pungent constituents of ginger. Thromb Res 2003; 111:259-265.
21. Kiuchi F, Iwakami S, Shibuya M, Hanaoka F, Sankawa U. Inhibition of prostaglandin and leukotriene biosynthesis by gingerols and diarylheptanoids. Chem Pharm Bull (Tokyo) 1992; 40:387-391.
22. Tjendraputra E, Tran VH, Liu-Brennan D, Roufogalis BD, Duke CC. Effect of ginger constituents and synthetic analogues on cyclooxygenase-2 enzyme in intact cells. Bioorg Chem 2001; 29:156-163.
23. Surh YJ, Lee E, Lee JM. Chemoprotective properties of some pungent ingredients present in red pepper and ginger. Mutat Res 1998; 402:259-267.
24. Ojewole JA. Analgesic, antiinflammatory and hypoglycaemic effects of ethanol extract of Zingiber officinale (Roscoe) rhizomes (Zingiberaceae) in mice and rats. Phytother Res 2006; 20:764-772.
25. Park KK, Chun KS, Lee JM, Lee SS, Surh YJ. Inhibitory effects of [6]-gingerol, a major pungent principle of ginger, on phorbol ester-induced inflammation, epidermal ornithine decarboxylase activity and skin tumor promotion in ICR mice. Cancer Lett 1998; 129:139-144.
26. Suekawa M, Aburada M, Hosoya E. Pharmacological studies on ginger. II. Pressor action of (6)-shogaol in anesthetized rats, or hindquarters, tail and mesenteric vascular beds of rats. J Pharmacobiodyn 1986; 9:842-852.
27. Thomson M, Al-Qattan KK, Al-Sawan SM, Alnaqeeb MA, Khan I, Ali M. The use of ginger (Zingiber officinale Rosc.) as a potential anti-inflammatory and antithrombotic agent. Prostaglandins Leukot Essent Fatty Acids 2002; 67:475-478.
28. Kim M, Miyamoto S, Yasui Y, Oyama T, Murakami A, Tanaka T. Zerumbone, a tropical ginger sesquiterpene, inhibits colon and lung carcinogenesis in mice. Int J Cancer 2009; 124:264-271.
29. Manju V, Nalini N. Chemopreventive efficacy of ginger, a naturally occurring anticarcinogen during the initiation, post-initiation stages of 1, 2 dimethylhydrazine-induced colon cancer. Clin Chim Acta 2005; 358:60-67.
30. Yoshimi N, Wang A, Morishita Y, et al. Modifying effects of fungal and herb metabolites on azoxymethane-induced intestinal carcinogenesis in rats. Jpn J Cancer Res 1992; 83:1273-1278.
31. Dias MC, Spinardi-Barbisan AL, Rodrigues MA, de Camargo JL, Teran E, Barbisan LF. Lack of chemopreventive effects of ginger on colon carcinogenesis induced by 1, 2-dimethylhydrazine in rats. Food Chem Toxicol 2006; 44:877-884.
32. Jiang Y, Turgeon DK, Wright BD, et al. Effect of ginger root on cyclooxygenase-1 and 15-hydroxyprostaglandin dehydrogenase expression in colonic mucosa of humans at normal and increased risk for colorectal cancer. Eur J Cancer Prev 2012; 5:455-460.
33. Zick SM, Turgeon DK, Vareed SK, et al. Phase II study of the effects of ginger root extract on eicosanoids in colon mucosa in people at normal risk for colorectal cancer. Cancer Prev Res (Phila) 2011; 4:1929-1937.
34. Zick SM, Djuric Z, Ruffin MT, et al. Pharmacokinetics of 6-gingerol, 8-gingerol, 10-gingerol, and 6-shogaol and conjugate metabolites in healthy human subjects. Cancer Epidemiol Biomarkers Prev 2008; 17:1930-1936.
35. U.S., Department of Health and Human Services NCI. Commmon Terminology Criteria for Adverse Events (CTCAE). 2009 September 15, 2009 v4.02 [cited 2013 January 22]; Version 4.0:[Available from: http://www.acrin.org/Portals/0/Administration/Regulatory/CTCAE_4.02_2009-09-15_QuickReference:57.pdf
36. Yang P, Chan D, Felix E, et al. Determination of endogenous tissue inflammation profiles by LC/MS/MS: COX- and LOX-derived bioactive lipids. Prostaglandins Leukot Essent Fatty Acids 2006; 75:385-395.
37. Vareed SK, Kakarala M, Ruffin MT, et al. Pharmacokinetics of curcumin conjugate metabolites in healthy human subjects. Cancer Epidemiol Biomarkers Prev 2008; 17:1411-1417.
38. Buczynski MW, Stephens DL, Bowers-Gentry RC, Grkovich A, Deems RA, Dennis EA. TLR-4 and sustained calcium agonists synergistically produce eicosanoids independent of protein synthesis in RAW264.7 cells. J Biol Chem 2007; 282:22834-22847.
39. Krishnan K, Ruffin MT, Normolle D, et al. Colonic mucosal prostaglandin E2 and cyclooxygenase expression before and after low aspirin doses in subjects at high risk or at normal risk for colorectal cancer. Cancer Epidemiol Biomarkers Prev 2001; 10:447-453.
40. Flynn DL, Rafferty MF, Boctor AM. Inhibition of human neutrophil 5-lipoxygenase activity by gingerdione, shogaol, capsaicin and related pungent compounds. Prostaglandins Leukot Med 1986; 24:195-198.
41. Lantz RC, Chen GJ, Sarihan M, Solyom AM, Jolad SD, Timmermann BN. The effect of extracts from ginger rhizome on inflammatory mediator production. Phytomedicine 2007; 14:123-128.
42. van Breemen RB, Tao Y, Li W. Cyclooxygenase-2 inhibitors in ginger (Zingiber officinale). Fitoterapia 2011; 82:38-43.
43. Kim SO, Chun KS, Kundu JK, Surh YJ. Inhibitory effects of [6]-gingerol on PMA-induced COX-2 expression and activation of NF-kappaB and p38 MAPK in mouse skin. Biofactors 2004; 21:27-31.
44. Jolad SD, Lantz RC, Chen GJ, Bates RB, Timmermann BN. Commercially processed dry ginger (Zingiber officinale): Composition and effects on LPS-stimulated PGE2 production. Phytochemistry 2005; 66:1614-1635.
45. Han YA, Song CW, Koh WS, et al. Anti-inflammatory effects of the Zingiber officinale roscoe constituent 12-dehydrogingerdione in lipopolysaccharide-stimulated Raw 264.7 cells. Phytother Res 2013; 27:1200-1205.
46. Li F, Nitteranon V, Tang X, et al. In vitro antioxidant and anti-inflammatory activities of 1-dehydro-[6]-gingerdione, 6-shogaol, 6-dehydroshogaol and hexahydrocurcumin. Food Chem 2012; 135:332-337.
47. Ha SK, Moon E, Ju MS, et al. 6-Shogaol, a ginger product, modulates neuroinflammation: A new approach to neuroprotection. Neuropharmacology 2012; 63:211-223.
48. Black CD, Herring MP, Hurley DJ, O'Connor PJ. Ginger (Zingiber officinale) reduces muscle pain caused by eccentric exercise. J Pain 2010; 11:894-903.
49. Drozdov VN, Kim VA, Tkachenko EV, Varvanina GG. Influence of a specific ginger combination on gastropathy conditions in patients with osteoarthritis of the knee or hip. J Altern Complement Med (NY) 2012; 18:583-588.
50. Liggett JL, Zhang X, Eling TE, Baek SJ. Anti-tumor activity of non-steroidal anti-inflammatory drugs: Cyclooxygenase-independent targets. Cancer Lett 2014; 346:217-224.
51. Baliga MS, Haniadka R, Pereira MM, et al. Update on the chemopreventive effects of ginger and its phytochemicals. Crit Rev Food Sci Nutr 2011; 51:499-523.
52. Butt MS, Sultan MT. Ginger and its health claims: Molecular aspects. Crit Rev Food Sci Nutr 2011; 51:383-393.
53. Citronberg J, Bostick RM, Ahearn TU, et al. Effects of ginger supplementation on cell cycle biomarkers in the normal-appearing colonic mucosa: Results from a pilot, randomized, controlled trial. Cancer Prev Res (Phila) 2013; 4:271-281.